With a single sign-on, Allergan EyeCueSM will enable you to:

  • Get answers about coding, coverage, and payment
  • Process insurance verification
  • Facilitate co-pay foundation referrals
  • Manage prior authorizations
  • Appeal denied claims
  • Order OZURDEX® online

If you have questions or need assistance, we're here to help!

  • Click here to download the new Allergan EyeCueSM Patient Enrollment Form
  • Click here to be contacted by a representative
  • Call 1-866-OZURDEX (1-866-698-7339)
  • Contact your local Reimbursement Business Advisor (RBA)

IMPORTANT SAFETY INFORMATION READ MORE

Allergan EyeCueSM is coming this fall.
Indications and Usage
Diabetic Macular Edema
OZURDEX® (dexamethasone intravitreal implant) is a corticosteroid indicated for the treatment of diabetic macular edema.

IMPORTANT SAFETY INFORMATION
Contraindications
Ocular or Periocular Infections:
OZURDEX® (dexamethasone intravitreal implant) is contraindicated in patients with active or suspected ocular or periocular
infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis),
vaccinia, varicella, mycobacterial infections, and fungal diseases.

Glaucoma:
OZURDEX® is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.

Torn or Ruptured Posterior Lens Capsule:
OZURDEX® is contraindicated in patients whose posterior lens capsule is torn or ruptured because of the risk of
migration into the anterior chamber. Laser posterior capsulotomy in pseudophakic patients is not a contraindication for OZURDEX® use.

Hypersensitivity:
OZURDEX® is contraindicated in patients with known hypersensitivity to any components of this product.

Warnings and Precautions
Intravitreal Injection‐related Effects: Intravitreal injections, including those with OZURDEX®, have been associated with endophthalmitis, eye inflammation,
increased intraocular pressure, and retinal detachments. Patients should be monitored regularly following the injection.

Steroid‐related Effects:
Use of corticosteroids including OZURDEX® may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma,
and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses.

Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

Adverse Reactions

Diabetic Macular Edema

Ocular adverse reactions reported by greater than or equal to 1% of patients in the two combined 3-year clinical trials following injection of OZURDEX® for
diabetic macular edema include: cataract (68%), conjunctival hemorrhage (23%), visual acuity reduced (9%), conjunctivitis (6%), vitreous floaters (5%),conjunctival
edema (5%), dry eye (5%), vitreous detachment (4%), vitreous opacities (3%), retinal aneurysm (3%), foreign body sensation (2%), corneal erosion (2%), keratitis
(2%), anterior chamber inflammation (2%), retinal tear (2%), eyelid ptosis (2%). Non-ocular adverse reactions reported by greater than or equal to 5% of patients
include: hypertension (13%) and bronchitis (5%).

Increased Intraocular Pressure:
IOP elevation greater than or equal to 10 mm Hg from baseline at any visit was seen in 28% of OZURDEX® patients versus 4%
of sham patients. 42% of the patients who received OZURDEX® were subsequently treated with IOP-lowering medications during the study versus 10% of
sham patients.

The increase in mean IOP was seen with each treatment cycle, and the mean IOP generally returned to baseline between treatment cycles (at the end of the
6-month period).

Cataracts and Cataract Surgery:
The incidence of cataract development in patients who had a phakic study eye was higher in the OZURDEX® group (68%) compared
with Sham (21%). The median time of cataract being reported as an adverse event was approximately 15 months in the OZURDEX® group and 12 months in the Sham
group. Among these patients, 61% of OZURDEX® subjects versus 8% of sham-controlled subjects underwent cataract surgery, generally between Month 18 and
Month 39 (Median Month 21 for OZURDEX® group and 20 for Sham) of the studies.

Retinal Vein Occlusion and Posterior Segment Uveitis

Adverse reactions reported by greater than 2% of patients in the first 6 months following injection of OZURDEX® for retinal vein occlusion and posterior segment uveitis
include: intraocular pressure increased (25%), conjunctival hemorrhage (22%), eye pain (8%), conjunctival hyperemia (7%), ocular hypertension (5%), cataract (5%),
vitreous detachment (2%), and headache (4%).

Increased IOP with OZURDEX® peaked at approximately week 8. During the initial treatment period, 1% (3/421) of the patients who received OZURDEX® required surgical
procedures for management of elevated IOP.

Please click here for full Prescribing Information.